beta-alanine has been researched along with Renal Insufficiency in 8 studies
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous." | 7.80 | Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014) |
| "Prospective, double-blind studies in orthopaedic patients have been conducted using the direct thrombin inhibitor dabigatran etexilate (hereafter referred to as dabigatran), with two doses investigated and approved for adults (220 mg and 150 mg once daily) to prevent venous thromboembolism (VTE)." | 4.88 | Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. ( Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N, 2012) |
| "Advantages of dabigatran, a thrombin inhibitor, for stroke prevention in patients with atrial fibrillation are numerous." | 3.80 | Impaired renal function and bleeding in elderly treated with dabigatran. ( Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014) |
| " Consequently, if renal function is impaired, there is a risk of drug accumulation that is highest for dabigatran followed by rivaroxaban and then apixaban and thus dosing recommendations are different." | 2.49 | Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. ( Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R, 2013) |
| " The first, monitoring, implies laboratory testing to assess the drug's effect and to adjust the dosage to maintain anticoagulation within the therapeutic interval." | 2.49 | The laboratory and the new oral anticoagulants. ( Tripodi, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schulman, S | 1 |
| Attia, JR | 1 |
| Pearce, R | 1 |
| Steiner, T | 1 |
| Böhm, M | 1 |
| Dichgans, M | 1 |
| Diener, HC | 1 |
| Ell, C | 1 |
| Endres, M | 1 |
| Epple, C | 1 |
| Grond, M | 1 |
| Laufs, U | 1 |
| Nickenig, G | 1 |
| Riess, H | 1 |
| Röther, J | 1 |
| Schellinger, PD | 1 |
| Spannagl, M | 1 |
| Veltkamp, R | 1 |
| Berthelot, E | 1 |
| Lavenu-Bombled, C | 1 |
| Orostegui-Giron, L | 1 |
| Desconclois, C | 1 |
| Assayag, P | 1 |
| Sardar, P | 1 |
| Chatterjee, S | 1 |
| Herzog, E | 1 |
| Nairooz, R | 1 |
| Mukherjee, D | 1 |
| Halperin, JL | 1 |
| Dahl, OE | 1 |
| Kurth, AA | 1 |
| Rosencher, N | 1 |
| Noack, H | 1 |
| Clemens, A | 1 |
| Eriksson, BI | 1 |
| Tripodi, A | 1 |
| Siegal, DM | 1 |
| Crowther, MA | 1 |
6 reviews available for beta-alanine and Renal Insufficiency
| Article | Year |
|---|---|
New anticoagulants in atrial fibrillation management.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-A | 2013 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatr | 2013 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; | 2014 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; | 2012 |
The laboratory and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigat | 2013 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alani | 2013 |
2 other studies available for beta-alanine and Renal Insufficiency
| Article | Year |
|---|---|
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
Impaired renal function and bleeding in elderly treated with dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |